Company-wide revenue
Reported revenue in 2021 ¥335.14B Reported revenue in 2025 ¥499.68B
- growth amount
- +¥164.54B
- growth annualized
- +10.5%
- growth total
- +49.1%
Japanese company profile · 4507
Shionogi & Co., Ltd.
In its FY2025 public filing, Shionogi & Co., Ltd. reports Prescription Pharmaceutical R&D, Sourcing, Manufacturing and Sales. The page shows business-level revenue and profit where the source disclosures support comparison.
Original Japanese company name: 塩野義製薬株式会社
English company name from the issuer's official source. English company name source
Reported company-wide figures
What does this company do?
What does this company do?
Shionogi & Co., Ltd.'s largest reported business by revenue in FY2025 was Prescription Pharmaceutical R&D, Sourcing, Manufacturing and Sales.
The business with the highest reported segment profit in FY2025 was Prescription Pharmaceutical R&D, Sourcing, Manufacturing and Sales.
FY2025 · fiscal year ended March 2026 View original filing ↗ The source document may be in Japanese.
Business structure
How does it make money?
| Business | Segment revenue | Revenue share | Segment profit (loss) |
|---|---|---|---|
| Prescription Pharmaceutical R&D, Sourcing, Manufacturing and Sales | ¥499.68B ↗ | 100.0% | ¥166.72B ↗ |
All values are in Japanese yen (JPY). No currency conversion is applied. FY2025 · fiscal year ended March 2026. Revenue and profit are shown only where the filing and data support a comparison.
Original Japanese label
- Prescription Pharmaceutical R&D, Sourcing, Manufacturing and Sales
- 医療用医薬品の研究開発、仕入、製造、販売並びにこれらの付随業務を事業内容とする単一事業
- Segment revenue
- セグメント収益
- Segment profit (loss)
- セグメント利益（損失）
Original Japanese label
- Prescription Pharmaceutical R&D, Sourcing, Manufacturing and Sales
- 医療用医薬品の研究開発、仕入、製造、販売並びにこれらの付随業務を事業内容とする単一事業
- Segment revenue
- セグメント収益
- Segment profit (loss)
- セグメント利益（損失）
Reported Segment revenue by business over time
Reported Segment revenue by business over time
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Prescription Pharmaceutical R&D, Sourcing, Manufacturing and Sales | ¥335.14B | ¥426.68B | ¥410.07B | ¥438.27B | ¥499.68B |
All amounts are in Japanese yen (JPY). Each figure links to the original Japanese filing. Blank cells indicate no comparable figure was disclosed. Business figures may not add up to consolidated figures.
What is growing?
What is growing?
Business revenue growth
Prescription Pharmaceutical R&D, Sourcing, Manufacturing and Sales
Reported revenue in 2021 ¥335.14B Reported revenue in 2025 ¥499.68B
- growth amount
- +¥164.54B
- growth annualized
- +10.5%
- growth total
- +49.1%
View original filing
This describes a reported period; it is not a forecast.
What has changed?
What has changed?
Not disclosed or not safely comparable in the available filings.
Source
Public filing
FY2025 · fiscal year ended March 2026
The source document may be in Japanese.
Filing ID: S100YF57
View original filing ↗Ask about this company
Ask about this company
The source document may be in Japanese.